Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes - PubMed (original) (raw)

Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes

E Celis et al. Proc Natl Acad Sci U S A. 1994.

Abstract

Cytotoxic T lymphocytes (CTLs) recognize peptide antigens associated with cell surface major histocompatibility complex (MHC) molecules. The identification of tumor cell-derived peptides capable of eliciting anti-tumor CTL responses would enable the design of antigen-specific immunotherapies. Our strategy to identify such potentially therapeutic peptides relies on selecting high-affinity MHC binders from known tumor-associated antigens. These peptides are subsequently tested for their ability to induce CTLs capable of killing tumor cells. With this strategy, we have identified a nine-residue epitope, derived from the product of the tumor-associated gene MAGE-3, which has the capacity to induce in vitro CTLs that kill melanoma and other tumor cell lines. These results show the primary in vitro induction of tumor-specific human CTLs and illustrate the feasibility of ex vivo antigen-specific approaches to the immunological therapy of cancer.

PubMed Disclaimer

References

    1. Adv Immunol. 1992;52:1-123 - PubMed
    1. J Exp Med. 1992 Nov 1;176(5):1453-7 - PubMed
    1. Nature. 1991 Sep 26;353(6342):326-9 - PubMed
    1. Science. 1991 Dec 13;254(5038):1643-7 - PubMed
    1. J Exp Med. 1989 Apr 1;169(4):1255-64 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources